The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
Written by
in
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
Written by
in